Technical Analysis for ZVRA - Zevra Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 4.82 | 0.42% | 0.02 |
Earnings due: May 20
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Death Cross | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Inside Day | Range Contraction | 0.42% | |
Pocket Pivot | Bullish Swing Setup | -1.43% | |
Outside Day | Range Expansion | -1.43% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Gapped Down | Weakness | 0.00% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 13 hours ago |
Possible NR7 | about 14 hours ago |
Possible Inside Day | about 14 hours ago |
Rose Above 10 DMA | about 17 hours ago |
2x Volume Pace | about 18 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/20/2024
Zevra Therapeutics, Inc. Description
Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Drugs Rare Diseases FDA Euphoriants Psychoactive Drugs Attention Deficit Hyperactivity Disorder Narcolepsy Amphetamine Methylphenidate Hydrocodone Idiopathic Hypersomnia Stimulants
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.28 |
52 Week Low | 3.89 |
Average Volume | 224,440 |
200-Day Moving Average | 5.23 |
50-Day Moving Average | 5.21 |
20-Day Moving Average | 4.75 |
10-Day Moving Average | 4.94 |
Average True Range | 0.23 |
RSI (14) | 45.65 |
ADX | 20.72 |
+DI | 17.24 |
-DI | 22.70 |
Chandelier Exit (Long, 3 ATRs) | 4.60 |
Chandelier Exit (Short, 3 ATRs) | 5.09 |
Upper Bollinger Bands | 5.20 |
Lower Bollinger Band | 4.29 |
Percent B (%b) | 0.58 |
BandWidth | 19.18 |
MACD Line | -0.05 |
MACD Signal Line | -0.10 |
MACD Histogram | 0.0457 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.06 | ||||
Resistance 3 (R3) | 5.08 | 5.03 | 5.02 | ||
Resistance 2 (R2) | 5.03 | 4.97 | 5.02 | 5.01 | |
Resistance 1 (R1) | 4.92 | 4.93 | 4.90 | 4.90 | 4.99 |
Pivot Point | 4.87 | 4.87 | 4.85 | 4.86 | 4.87 |
Support 1 (S1) | 4.76 | 4.81 | 4.74 | 4.74 | 4.65 |
Support 2 (S2) | 4.71 | 4.77 | 4.70 | 4.63 | |
Support 3 (S3) | 4.60 | 4.71 | 4.62 | ||
Support 4 (S4) | 4.58 |